Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls. First-line bortezomib (Velcade) appears to ...

Final data from the ECWM-1 (NCT01788020) showed that adding bortezomib to dexamethasone, rituximab and cyclophosphamide (DRC) does not convey a survival benefit for patients with Waldenström ...

Multiple myeloma is the second most common hematologic malignancy and remains incurable, despite advances in chemotherapy and stem cell transplantation. Bortezomib, a novel proteasome inhibitor, is ...

Please provide your email address to receive an email when new articles are posted on . The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young ...

Novel therapy has dramatically changed the outcome of patients with myeloma. Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the ...

Purpose: Renal impairment is a frequent complication of multiple myeloma (MM) and is associated with significant morbidity and increased early death rate. Bortezomib is active and well tolerated in ...

The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth. Combining carfilzomib, a broad-spectrum drug ...

Please provide your email address to receive an email when new articles are posted on . Response-adapted intensification treatment with a bortezomib-based regimen improved PFS among patients with ...

Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease PLD with bortezomib is superior to bortezomib monotherapy ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...